Granted Patent
B2
US 12,491,255 · App. 17/768,711 · Granted Dec 9, 2025
EPCAM binding fibronectin type III domains
Inventors:
Russell C. Addis (Philadelphia, PA); Robert Kolakowski (Philadelphia, PA); Swapnil Kulkarni (Philadelphia, PA); Steven G. Nadler (Philadelphia, PA); Karyn O'Neil (Philadelphia, PA); Yao Xin (Philadelphia, PA)
Assignee:
ARO Biotherapeutics Company
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind EpCAM, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the molecules.
Claims (13)
1 . A polypeptide comprising the amino acid sequence of SEQ ID NOs: 33, 34, 35, 36, 37, 38, 39, or any combination thereof.
2 . The polypeptide of claim 1 , further comprising one or more polypeptide selected from SEQ ID NOs: 33, 34, 35, 36, 37, 38, or 39.
3 . The polypeptide of claim 1 , wherein the polypeptide is linked to a nucleic acid molecule selected from a siRNA nucleic acid molecule, an antisense nucleic acid molecule, a DNA oligonucleotide, or a RNA oligonucleotide.
4 . The polypeptide of claim 1 , wherein the polypeptide is conjugated to a detectable label, a therapeutic agent, or any combination thereof.
5 . The polypeptide of claim 4 , wherein the detectable label is a radioactive isotope, magnetic beads, metallic beads, colloidal particles, a fluorescent dye, an electron-dense reagent, an enzyme, biotin, digoxigenin, or hapten.
6 . The polypeptide of claim 4 , wherein the therapeutic agent is a chemotherapeutic agent, a drug, one or more FN3 domains, a growth inhibitory agent, a toxin, a radioactive isotope, an anti-tubulin agent, a polynucleotide, a siRNA molecule, an antisense molecule, a RNA molecule, a DNA molecule, DNA minor groove binders, DNA replication inhibitors, alkylating agents, antibiotics, antifolates, antimetabolites, chemotherapy sensitizers, topoisomerase inhibitors, or a vinca alkaloid.
7 . The polypeptide of claim 1 , further comprising a methionine at the N-terminus of the polypeptide.
8 . The polypeptide of claim 1 , wherein the polypeptide is coupled to a half-life extending moiety.
9 . The polypeptide of claim 8 , wherein the half-life extending moiety is an albumin binding molecule, a polyethylene glycol (PEG), albumin, albumin variant, at least a portion of an Fc region of an immunoglobulin.
10 . An isolated polynucleotide encoding the polypeptide of claim 1 .
11 . A vector comprising the polynucleotide of claim 10 .
12 . A host cell comprising the vector of claim 11 .
13 . A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 26, 2022
From: ADDIS, RUSSELL C.; KOLAKOWSKI, ROBERT; KULKARNI, SWAPNIL; NADLER, STEVEN G.; O'NEIL, KARYN; XIN, YAO
To: ARO BIOTHERAPEUTICS COMPANY
Reel/Frame 061551/0760 →
Continuity (2)
Provisional Application
62914654
· Oct 14, 2019
References Cited (400)
US 4281061A
· Zuk et al.
· 1981
[cited by applicant]
US 5223409A
· Ladner et al.
· 1993
[cited by applicant]
US 5643763A
· Dunn et al.
· 1997
[cited by applicant]
US 5643768A
· Kawasaki
· 1997
[cited by applicant]
US 5658727A
· Barbas et al.
· 1997
[cited by applicant]
US 5691157A
· Gong et al.
· 1997
[cited by applicant]
US 5846456A
· Liu
· 1998
[cited by applicant]
US 5856456A
· Whitlow et al.
· 1999
[cited by applicant]
US 6018030A
· Ferrari et al.
· 2000
[cited by applicant]
US 6162903A
· Trowern et al.
· 2000
[cited by applicant]
US 6172197B1
· McCafferty et al.
· 2001
[cited by applicant]
US 6355776B1
· Ferrari et al.
· 2002
[cited by applicant]
US 6462189B1
· Koide
· 2002
[cited by applicant]
US 6472147B1
· Janda et al.
· 2002
[cited by applicant]
US 6521427B1
· Evans
· 2003
[cited by applicant]
US 6582915B1
· Griffiths et al.
· 2003
[cited by applicant]
US 6670127B2
· Evans
· 2003
[cited by applicant]
US 6673901B2
· Koide
· 2004
[cited by applicant]
US 6703199B1
· Koide
· 2004
[cited by applicant]
US 6818418B1
· Lipovsek et al.
· 2004
[cited by applicant]
US 6846655B1
· Wagner et al.
· 2005
[cited by applicant]
US 6969108B2
· Fukumoto et al.
· 2005
[cited by applicant]
US 7078490B2
· Koide
· 2006
[cited by applicant]
US 7115396B2
· Lipovsek et al.
· 2006
[cited by applicant]
US 7119171B2
· Koide
· 2006
[cited by applicant]
US 7153661B2
· Koide
· 2006
[cited by applicant]
US 7288638B2
· Jure-Kunkel et al.
· 2007
[cited by applicant]
US 7427672B2
· Imanishi et al.
· 2008
[cited by applicant]
US 7709214B2
· Freeman et al.
· 2010
[cited by applicant]
US 7794710B2
· Chen et al.
· 2010
[cited by applicant]
US 7842476B2
· McGregor et al.
· 2010
[cited by applicant]
US 7943743B2
· Korman et al.
· 2011
[cited by applicant]
US 8217149B2
· Irving et al.
· 2012
[cited by applicant]
US 8278419B2
· Jacobs et al.
· 2012
[cited by applicant]
US 8293482B2
· Jacobs et al.
· 2012
[cited by applicant]
US 8552154B2
· Freeman et al.
· 2013
[cited by applicant]
US 8569227B2
· Jacobs
· 2013
[cited by applicant]
US 8741295B2
· Olive
· 2014
[cited by applicant]
US 8779108B2
· Queva et al.
· 2014
[cited by applicant]
US 8981063B2
· Chen
· 2015
[cited by applicant]
US 9156887B2
· Jacobs
· 2015
[cited by applicant]
US 9175082B2
· Zhou et al.
· 2015
[cited by applicant]
US 9200273B2
· Diem et al.
· 2015
[cited by applicant]
US 9212224B2
· Cogswell et al.
· 2015
[cited by applicant]
US 9326941B2
· Chae et al.
· 2016
[cited by applicant]
US 9546368B2
· Bennett et al.
· 2017
[cited by applicant]
US 9644023B2
· Torres et al.
· 2017
[cited by applicant]
US 9695228B2
· Mark et al.
· 2017
[cited by applicant]
US 9897612B2
· Diem et al.
· 2018
[cited by applicant]
US 20040259781A1
· Chiquet-Ehrismann et al.
· 2004
[cited by applicant]
US 20050004029A1
· Garcia
· 2005
[cited by applicant]
US 20050255548A1
· Lipovsek et al.
· 2005
[cited by applicant]
US 20060040278A1
· Cojocaru et al.
· 2006
[cited by applicant]
US 20060246059A1
· Lipovsek et al.
· 2006
[cited by applicant]
US 20060270604A1
· Lipovsek et al.
· 2006
[cited by applicant]
US 20080015339A1
· Lipovsek et al.
· 2008
[cited by applicant]
US 20080220049A1
· Chen et al.
· 2008
[cited by applicant]
US 20090042906A1
· Huang et al.
· 2009
[cited by applicant]
US 20090176654A1
· Cappuccilli et al.
· 2009
[cited by applicant]
US 20090274693A1
· Gilmer et al.
· 2009
[cited by applicant]
US 20090311803A1
· Way et al.
· 2009
[cited by applicant]
US 20100093662A1
· Defaye et al.
· 2010
[cited by applicant]
US 20100254989A1
· Bossenmaier et al.
· 2010
[cited by applicant]
US 20110081345A1
· Moore et al.
· 2011
[cited by applicant]
US 20110118144A1
· Hyun et al.
· 2011
[cited by applicant]
US 20120270797A1
· Wittrup et al.
· 2012
[cited by applicant]
US 20120315639A1
· Deng et al.
· 2012
[cited by applicant]
US 20120321666A1
· Cooper et al.
· 2012
[cited by applicant]
US 20130226834A1
· Gannalo, II
· 2013
[cited by applicant]
US 20130273561A1
· Walker et al.
· 2013
[cited by applicant]
US 20150191543A1
· Wu et al.
· 2015
[cited by applicant]
US 20150252097A1
· Camphausen et al.
· 2015
[cited by applicant]
US 20160303256A1
· Liu
· 2016
[cited by applicant]
US 20170281795A1
· Geall et al.
· 2017
[cited by applicant]
US 20190070322A1
· Bander
· 2019
[cited by applicant]
US 20190175651A1
· Lee et al.
· 2019
[cited by applicant]
US 20190184028A1
· Dudkin
· 2019
[cited by examiner]
US 20190256575A1
· Chen et al.
· 2019
[cited by applicant]
CN 102076713A
· 2011
[cited by applicant]
CN 103827361A
· 2014
[cited by applicant]
CN 105907719A
· 2016
[cited by applicant]
EP 0985039A2
· 2000
[cited by applicant]
EP 1137941A1
· 2001
[cited by applicant]
EP 1210428A1
· 2002
[cited by applicant]
EP 1266025A1
· 2002
[cited by applicant]
EP 2935329A1
· 2015
[cited by applicant]
JP 2011507543A
· 2011
[cited by applicant]
JP 2011517314A
· 2011
[cited by applicant]
JP 2011520961A
· 2011
[cited by applicant]
JP 2011522517A
· 2011
[cited by applicant]
JP 2012507295A
· 2012
[cited by applicant]
JP 2014530014A
· 2014
[cited by applicant]
JP 2016504291A
· 2016
[cited by applicant]
KR 1020160067966A
· 2016
[cited by applicant]
WO 9638557A1
· 1996
[cited by applicant]
WO 2001014557A1
· 2001
[cited by applicant]
WO 0164942A1
· 2001
[cited by applicant]
WO 0232925A2
· 2002
[cited by applicant]
WO 03104418A2
· 2003
[cited by applicant]
WO 2004029224A2
· 2004
[cited by applicant]
WO 2004058821A2
· 2004
[cited by applicant]
WO 2005018534A2
· 2005
[cited by applicant]
WO 2005042708A2
· 2005
[cited by applicant]
WO 2007000671A2
· 2007
[cited by applicant]
WO 2007085815A2
· 2007
[cited by applicant]
WO 2008066752A2
· 2008
[cited by applicant]
WO 2008079973A2
· 2008
[cited by applicant]
WO 2008127710A2
· 2008
[cited by applicant]
WO 2008156642A1
· 2008
[cited by applicant]
WO 2009023184A2
· 2009
[cited by applicant]
WO 2009058379A2
· 2009
[cited by applicant]
WO 2009083804A2
· 2009
[cited by applicant]
WO 2009085462A1
· 2009
[cited by applicant]
WO 2009086116A2
· 2009
[cited by applicant]
WO 2009102421A2
· 2009
[cited by applicant]
WO 2009111691A2
· 2009
[cited by applicant]
WO 2009126834A2
· 2009
[cited by applicant]
WO 2009133208A1
· 2009
[cited by applicant]
WO 2009142773A2
· 2009
[cited by applicant]
WO 2010039248A1
· 2010
[cited by applicant]
WO 2010051274A2
· 2010
[cited by applicant]
WO 2010051310A2
· 2010
[cited by applicant]
WO 2010060095A1
· 2010
[cited by applicant]
WO 2010093627A3
· 2010
[cited by applicant]
WO 2010115202A2
· 2010
[cited by applicant]
WO 2010115551A1
· 2010
[cited by applicant]
WO 2011005133A1
· 2011
[cited by applicant]
WO 2011110642A2
· 2011
[cited by applicant]
WO 2011130324A1
· 2011
[cited by applicant]
WO 2011131746A2
· 2011
[cited by applicant]
WO 2011137319A2
· 2011
[cited by applicant]
WO 2011151412A1
· 2011
[cited by applicant]
WO 2012016245A2
· 2012
[cited by applicant]
WO 2012162418A1
· 2012
[cited by applicant]
WO 2013049275A1
· 2013
[cited by applicant]
WO 2014081944A2
· 2014
[cited by applicant]
WO 2014081954A1
· 2014
[cited by applicant]
WO 2014100079A1
· 2014
[cited by applicant]
WO 2014165082A2
· 2014
[cited by applicant]
WO 2014165093A2
· 2014
[cited by applicant]
WO 2014189973A2
· 2014
[cited by applicant]
WO 2014209804A1
· 2014
[cited by applicant]
WO 2015057545A2
· 2015
[cited by applicant]
WO 2015061668A1
· 2015
[cited by applicant]
WO 2015089073A2
· 2015
[cited by applicant]
WO 2015092393A2
· 2015
[cited by applicant]
WO 2015109124A2
· 2015
[cited by applicant]
WO 2015143199A1
· 2015
[cited by applicant]
WO 2015195163A1
· 2015
[cited by applicant]
WO 2016000619A1
· 2016
[cited by applicant]
WO 20160004043A1
· 2016
[cited by applicant]
WO WO2016019707A1
· 2016
[cited by applicant]
WO 2016086021A1
· 2016
[cited by applicant]
WO 2016086036
· 2016
[cited by applicant]
WO 2016179534
· 2016
[cited by applicant]
WO WO20160179518A2
· 2016
[cited by applicant]
WO 2016197071A1
· 2016
[cited by applicant]
WO 2017011618A1
· 2017
[cited by applicant]
WO WO20170143286A1
· 2017
[cited by applicant]
WO 2017223180A2
· 2017
[cited by applicant]
WO 2018148501A1
· 2018
[cited by applicant]
WO WO2021030763
· 2021
[cited by applicant]
WO WO2021030778
· 2021
[cited by applicant]
WO WO2021076546A1
· 2021
[cited by applicant]
WO WO2021076574A2
· 2021
[cited by applicant]
Skerra, et al., “Engineered protein scaffolds for molecular recognition,” Journal of Molecular Recognition, 13: 167-187 (2000).
[cited by applicant]
Koide, et al., “The Fibronectin Type III Domain as a Scaffold for Novel Binding Proteins,” Journal of Molecular Biology, 284: 1141-1151 (1998).
[cited by applicant]
Karatan, et al., “Molecular Recognition Properties of FN3 Mono bodies that Bind the Src SH3 Domain,” Chemistry & Biology, 11: 835-844 (2004).
[cited by applicant]
Parker, et al., “Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two,” Protein Engineering, Design & S…
[cited by applicant]
Siggers et al. Conformational dynamics in loop swap mutants of homologous fibronectin type III domains. Biophys J. Oct. 1, 2007 ;93(7):2447-56.
[cited by applicant]
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol. 18(1 ):34-9, 2000.
[cited by applicant]
Attwood TK. Genomics. The Babel of bioinformatics. Science. 290(5491 ):471-473, 2000.
[cited by applicant]
Miller et al Ligand binding to proteins: the binding landscape model. Protein Sci. Oct. 1997;6(10):2166-79.
[cited by applicant]
Kuntz. Structure-based strategies for drug design and discovery. Science. 1992 257(5073):1078-1082.
[cited by applicant]
Koivunen et al. Identification of Receptor Ligands with Phage Display Peptide Libraries J Nucl Med; 40:883-888, 1999.
[cited by applicant]
Reiss et al. Inhibition of platelet aggregation by grafting RGD and KGD sequences on the structural scaffold of small disulfide-rich proteins. Platelets 17(3):153-157, 2006.
[cited by applicant]
Helms et al. Destabilizing loop swaps in the CDRs of an immunoglobulin VL domain. Protein Science 4:2073-2081, 1995.
[cited by applicant]
Bass, et al., “Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Properties,” Proteins: Structure, Function, and Genetics, 8: 309-314 (1990).
[cited by applicant]
Clarke, et al., “Folding and Stability of a Fibronectin Type III Domain of Human Tenascin,” Journal of Molecular Biology, 270: 771-778 (1997).
[cited by applicant]
Dehouck, et al., “Fast and accurate predictions of protein stability changes upon mutations using statistical potentials and neural networks: PoPMuSiC-2.0, Bioinformatics,” 25(19): 2537-2543 (2009).
[cited by applicant]
Dineen, et al., “The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer,” BMC Cancer, 8: 352-361 (2008).
[cited by applicant]
Dutta, et al., “High-affinity fragment complementation of a fibronectin type III domain and its application to stability enhancement,” Protein Science, 14: 2838-2848 (2005).
[cited by applicant]
Garrard, et al., “Selection of an anti-IGF-1 Fab from a Fab phage library created by mutagenesis of multiple CDR loops,” Gene, 128: 103-109 (1993).
[cited by applicant]
Getmanova, et al., “Antagonists to Human and Mouse Vascular Endothelial Growth Factor Receptor 2 Generated by Directed Protein Evolution In Vitro,” Chemistry & Biology, 13: 549-556 (2006).
[cited by applicant]
Hackel, et al., “Stability and CDR Composition Biases Enrich Binder Functionality Landscapes,” Journal of Molecular Biology, 401: 84-96 (2010).
[cited by applicant]
Hackel, et al., “Picomolar Affinity Fibronectin Domains Engineered Utilizing Loop Length Diversity, Recursive Mutagenesis, and Loop Shuffling,” Journal of Molecular Biology, 381: 1238-1252 (2008).
[cited by applicant]
Knappik, et al., “Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides,” Journal of Molecular Biology, 296: 57-86 (2002).
[cited by applicant]
Koide, et al., Teaching an Old Scaffold New Tricks: Monobodies Constructed Using Alternative Surfaces of the FN3 Scaffold, Journal of Molecular Biology, 415: 393-405 (2012).
[cited by applicant]
Lipovsek, et al., “Evolution of an Interloop Disulfide Bond in High-Affinity Antibody Mimics Based on Fibronectin Type III Domain and Selected by Yeast Surface Display: Molecular Convergence with Single-Domain Camelid a…
[cited by applicant]
C.N. Pace, “Determination and Analysis of Urea and Guanidine Hydrochloride Denaturation Curves,” Methods in Enzymology, 131: 266-280 (1986).
[cited by applicant]
Steiner, et al., “Efficient Selection of DARPins with Sub-nonomolar Affinities using SRP Phage Display,” Journal of Molecular Biology, 382: 1211-1227 (2008).
[cited by applicant]
Xu, et al., “Directed Evolution of High-Affinity Antibody Mimics Using mRNA Display,”Chemistry & Biology, 9: 933-942 (2002).
[cited by applicant]
Cota, et al., “Two Proteins with the Same Structure Respond very Differently to Mutation: The Role of Plasticity in Protein Stability”, Journal of Molecular Biology, 302, 713-725 (2000).
[cited by applicant]
Hamill et al., “The Effect of Boundary Selection on the Stability and Folding of the Third Fibronectin Type III Domain from Human Tenascin”, Biochemistry, 37: 8071-8079 (1998).
[cited by applicant]
Garcia-Ibilcieta, et al., “Simple method for production of randomized human tenth fibronectin domain III libraries for use in combinatorial screening procedures,” Bio Technologies, 44: 559-562 (2008).
[cited by applicant]
Van den Burg et al., “Selection of mutations for increased protein stability”, Curr. Opin. Biotech. 13:333-337 (2002).
[cited by applicant]
GenBank Accession No. NP_002151.
[cited by applicant]
Slonomics® Technology Website “https://www.morphosys.com/science/drug-development-capabilities/slonomics”.
[cited by applicant]
UniProt Accession No. P10039.
[cited by applicant]
SwissProt Accession No. P00533.2, “Epidermal Growth Factor Receptor,” pp. 1-49 (Jun. 11, 2014).
[cited by applicant]
Turke et al., “Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC,” Cancer Cell, vol. 17, pp. 77-88 (2010).
[cited by applicant]
Ullrich et al., “Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified Jene in A431 epiderrnoid carcinoma cells,” Nature, vol. 309, pp. 418-425 (1984).
[cited by applicant]
Zhang et al., “Complete disulfide bond assignment of a recombinant immunoglobulin G4 monoclonal antibody,” Analytical Biochemistry, vol. 311, pp. 1-9 (2002).
[cited by applicant]
Adjei et al., “Early Clinical Development of ARQ197, a Selective, Non-ADP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers,” The Oncologist, vol. 16, pp. 788-799 (2011).
[cited by applicant]
Basel GA et al., “Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer,” Journal of Clinical Oncology, vol. 23, No. 11, pp. 2445-2459 (2005).
[cited by applicant]
Batley et al., “Inhibition of FGF-1 Receptor Tyrosine Kinase Activity By PD 161570, a New Protein-Tyrosine Kinase hhibitor,” Life Sciences, vol. 62, No. 20, pp. 143-150 (1998).
[cited by applicant]
Bean et al., “MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired esistance to gefilinib or erlotinib,” Proceedings of the National Academy of Science, vol. 104, No. 52, pp.…
[cited by applicant]
Cappuzzo et al., “Epidermal Growth Factor Receptor Gene and Protein and Gefilinib Sensitivity in Non-small-Cell ung Cancer,” Journal of the National Cancer Institute, vol. 97, pp. 643-655 (2005).
[cited by applicant]
Christensen et al., “c-Met as a target for human cancer and characterization of inhibitors for therapeutic ntervention,” Cancer Letters, vol. 225, pp. 1-26 (2005).
[cited by applicant]
Cooper et al., “Molecular cloning of a new transforming gene from a chemically transformed human cell line,” Nature, vol. 311, pp. 29-33 (1984).
[cited by applicant]
DeRoock et al., “Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis,” Lancet Onc…
[cited by applicant]
Downward et al., “Autophosphorylation sites on the epidermal growth factor receptor,” Nature, vol. 311, pp. 183-485 ( 1984).
[cited by applicant]
Engelman et al., “MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling,” Science, vol. 316, pp. 1039-1043 (2007).
[cited by applicant]
Ferguson, Kathryn M., “Structure-Based View of Epidermal Growth Factor Receptor Regulation,” Annual Review of Biophysics, vol. 37, pp. 535-373 (2008).
[cited by applicant]
GenBank Accession No. NP 001120972.
[cited by applicant]
International Search Report and Written Opinion from International Application No. PCT/US2021/030863 dated Oct. 29, 2021, International Filing Date May 5, 2021.
[cited by applicant]
Non-Final Office Action dated Dec. 1, 2022, from U.S. Appl. No. 17/070,337.
[cited by applicant]
Notice of Allowance dated Nov. 28, 2022 in U.S. Appl. No. 17/070,020.
[cited by applicant]
Gill et al., “Monoclonal Anti-epidermal Growth Factor Receptor Antibodies Which Are Inhibitors of Epidermal Growth acier Binding and Antagonists of Epidermal Growth Factor-stimulated tyrosine Protein Kinase Activity, Th…
[cited by applicant]
Goldstein et al., “Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human umor kenografl model,” Clinical Cancer Research, vol. 1, pp. 1311-1318 (1995).
[cited by applicant]
Grünwald et al., “Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment,” Journal of he National Cancer Institute, vol. 95, No. 12, pp. 851-867 (2003).
[cited by applicant]
Hirsch et al., “Combination of EGFR gene copy number and protein expression predicts outcome for advanced non- , mall-cell lung cancer patients treated with gefitnib,” Annals of Oncology, vol. 18, pp. 752-760 (2007).
[cited by applicant]
Hynes et al., “ERBB Receptors and Cancer: the Complexity of Targeted Inhibitors,” Nature Reviews, vol. 5, pp. 341-356 (2005).
[cited by applicant]
Chimu Ra et al., “Expression of c-mel/HGF Receptor in Human Non-small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic Significance,” Japan Journal of Cancer Research, vol. 87. pp. 1063-1069 (1996).
[cited by applicant]
Jänne et al., “Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Non-small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibit…
[cited by applicant]
Jacobs et al., “FN3 Domain Engineering”, Protein Engineering, pp. 145-162, 2012.
[cited by applicant]
Li et al., “Skin toxicities associated with epidermal growth factor receptor inhibitors,” Target Oncology, vol. 4, pp. 107-119 (2009).
[cited by applicant]
Linardou et al., “Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC,” National Review of :: linical Oncology, vol. 6, pp. 352-366 (2009).
[cited by applicant]
Ma et al., “c-Met: Structure, functions and potential for therapeutic inhibition,” Cancer and Metastasis Reviews, vol. 22 pp. 309-325 (2003).
[cited by applicant]
Mendelsohn et al., “Epidermal Growth Factor Receptor Targeting in Cancer,” Seminars in Oncology, vol. 33, pp. 369-385 (2006).
[cited by applicant]
Mendelsohn et al., “The EGF receptor family as targets for cancer therapy,” Oncogene, vol. 19, pp. 6550-6565 2000).
[cited by applicant]
Mättä et al., “Proteolytic Cleavage and Phosphorylation of a Tumor-associated ErbB4 Isoform Promote Ligand-ndependent Survival and Cancer Cell Growth,” Molecular Biology, vol. 17, pp. 67-79 (2006).
[cited by applicant]
NCBI Reference Sequence NP _005219.2, “Epidermal Growth Factor Receptor Isoform a Precursor [
[cited by applicant]
Panek et al.,“In Vitro Pharmacological Characterization of PD 166285, a New Nanomolar Potent and Broadly Active Protein Tyrosine Kinase Inhibitor,” The Journal of Pharmacology and Experimental Therapeutics, vol. 283, No…
[cited by applicant]
Peters et al., “MET: a promising anticancer therapeutic target,” Nature Reviews Clinical Oncology, vol. 9, pp. 314-326 (2012).
[cited by applicant]
Prewett et al., “Mouse-Human chimeric Anti-Epidermal Growth Factor Receptor Antibody C225 Inhibits the Growth Jf Human Renal Cell Carcinoma Xenografts in Nude Mice,” Clinical Cancer Research, vol. 4, pp. 2957-2966 (1998…
[cited by applicant]
Riel Yet al., “Clinical Course of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib,” Clinical Cancer Research, vol. 12, No. …
[cited by applicant]
Sakakura et al., “Gains, Losses, and Amplifications of Genomic Materials in Primary Gastric Cancers Analyzed by :; omparative Genomic Hybridization,” Genes, Chromosomes & Cancer, vol. 24, pp. 299-305 (1999).
[cited by applicant]
Schmidt et al., “Novel mutations of the MET proto-0ncogene in papillary rental carcinomas,” Oncogene, vol. 18, pp. ]343-2350 (1999).
[cited by applicant]
Siegfried et al., “The Clinical Significance of Hepatocyte Growth Factor for Non-Small Cell Lung Cancer,” Annals of Thoracic Surgery, vol. 66, pp. 1915-1918 (1998).
[cited by applicant]
Sierra et al., “c-MET as a potential therapeutic target and biomarker in cancer,” Therapeutic Advances in Medical :: >ncology, vol. 3, No. 51, pp. 521-535 (2011).
[cited by applicant]
Stamos et al., “Crystal structure of the HGF b-chain in complex with the Serna domain of the Met receptor,” The EMBO Journal, vol. 23, pp. 2325-2335 (2004).
[cited by applicant]
Mamluk et al., “Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2”, mAbs, 2(2), pp. 199-208, 2010.
[cited by applicant]
Klein et al. “Abstract LB-312: Bispecific Centyrin Simultaneously targeting EGFR and c--Met demonstrates improved ô€?'ctivity compared to the mixture of single agents”, Cancer Research, 73 (8 Supplement), Abstract LB-31…
[cited by applicant]
Jacobs et al., “Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics”, Protein Engineering, Design & Selection, vol. 28, No. 10, pp. 385-393, 2015.
[cited by applicant]
Notice of Allowance mailed Mar. 3, 2020 in U.S. Appl. No. 15/840,303.
[cited by applicant]
Makkouk Amani et al: “Rationale for anti-CD137 cancer immunotherapy”, European Journal of Cancer, Elsevier, Amsterdam, NL, vol. 54, Jan. 2, 2016 (Jan. 2, 2016), pp. 112-119, XP029401784, ISSN: 0959-8049, DOI: 10.1016/j.…
[cited by applicant]
Shalom D. Goldberg et al: “Engineering a targeted delivery platform using Centyrins”, Protein Engineering, Design and Selection, Oct. 13, 2016 (Oct. 13, 2016), XP055384705, GB ISSN: 1741-0126, DOI: 10.1093/protein/gzw05…
[cited by applicant]
Burton Earle Barnett et al: “Disclosures”, Blood, vol. 128, No. 22, Dec. 2, 2016 (Dec. 2, 2016), pp. 4557-4557, XP055711182, US ISSN: 0006-4971, doi: 10.1182/blood.V128.22.4557.4557 *abstract*.
[cited by applicant]
Final Office Action mailed on Jul. 10, 2020 in U.S. Appl. No. 15/637,276.
[cited by applicant]
Zucali, et al., “Role of cMET expression in non-small-cell lung cancer patients treated with eGFR tyrosine kinase inhibitors”, Annals of Anocology (2008) 19:: 1605-1612.
[cited by applicant]
Burgess et al., “Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single…
[cited by applicant]
Lazar et al., “Transforming growth factor alpha: mutation of aspartic acid 47 and leucie 48 results in different biological activities”, Mol Cell Biol. (1988) 8: pp. 1247-1252.
[cited by applicant]
Brown et al., “Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation”, J. Immuno. (1996) pp. 3285-3291.
[cited by applicant]
Rudikoff el al., “Single amino acid substitution altering antigen-binding specificity”, Proc Natl Acad Sci (1982) 79(6): pp. 1979-1983.
[cited by applicant]
Vajdos et al., “Comprehensive funtional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenisis”, J. Mol. Biol. (2002) 32(2): pp. 415-428.
[cited by applicant]
Non-Final Office Action mailed on Jul. 9, 2021 in U.S. Appl. No. 16/821,064.
[cited by applicant]
Rybalov et al., “PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent Prostate Cancer after Radiotherapy”, Int. J. Mol. Sci. (2014) 15, pp. 6046-6061.
[cited by applicant]
Non-Final Office Action mailed on Feb. 3, 2021 in U.S. Appl. No. 16/218,990.
[cited by applicant]
Final Office Action mailed on Jul. 21, 2020 in U.S. Appl. No. 16/218,990.
[cited by applicant]
Lejon et al., “Structural basis for the binding of naproxen to human serum albumin in the presence of fatty acids and the GA module”, Acta Cryst. (2008) F pp. 64-69.
[cited by applicant]
Lee et al., “A Glu-ruea-Lys Ligand-conjugated Lipid nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo”, Molecular Therapy-Nucleic Acids (2016) 5, e348: pp. 1-11.
[cited by applicant]
Pace, “Determination and Analysis of Urea and Guanidine Hydrochloride Denaturation Curves”, Methods in Enzymology (1986) vol. 131, pp. 266-280.
[cited by applicant]
Chen et al., “Cell-Surface Display of Heterologous Proteins: From High-Throughput Screening to Environmental Applications”, Biotechnology and Bioengineering, (2002) vol. 79, No. 5, pp. 496-503.
[cited by applicant]
Mattheakis et al., “An in vitro polysome display system for identifying ligands from very large peptide libraries”, Proc. Natl. Acad. Sci. (1994) Vo.. 91, pp. 9022-9026.
[cited by applicant]
Hoogenboom et al., “Natural and designer binding sites made by phage display technology” Immunology Today (2000) vol. 21, No. 8, pp. 371-378.
[cited by applicant]
Smith, “Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface.”, Association of Science (1985) vol. 228, pp. 1315(3).
[cited by applicant]
Capellas, “Enzymatic Condensation of Cholecystokinin CCK-8 (4-6) and CCK-8 (7-8) Peptide Fragments in Organic Media”, Biotechnology and Bioengineering (1997) vol. 56, No. 4, pp. 456-463.
[cited by applicant]
Itoh, et al., “Application of Inverse Substrates to Trypsin-Catalyzed Peptid Synthesis”, Bioorganic Chemistry (1996) 24, 0007, pp. 59-68.
[cited by applicant]
Kumaran et al., “Confrmationally driven protease-catalyzed splicing of peptide segments: V8 protease-mediated syntheses of fragments derived from thermolysin and ribonuclease A”, Protein Science, (1997) 6: pp. 2233-2241.
[cited by applicant]
Kunkel et al., “Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection”, Methods In Enzymology, (1987) vol. 154 pp. 367-375.
[cited by applicant]
Wattanachaisaereekul, “Production of Polyketides by
[cited by applicant]
Hackel et al., “Use of 64Cu-Labeled Fibronectin Domain with EGFR-Overexpressing Tumor Xenograft: Molecular Imaging1”, Radiology (2012) vol. 263:No. 1 pp. 179-188.
[cited by applicant]
Non-Final Office Action mailed on Aug. 18, 2021 in U.S. Appl. No. 16/801,787.
[cited by applicant]
McCracken, “Non-invasive monitoring of hematopoietic reconstitution and immune cell function through Positron Emission Tomography” University of California, Los Angeles, Dissertaton ProQuest LLC (2014) pp. 1-202.
[cited by applicant]
Natarajan, et al., “A Novel Engineered Anti-CD20 Tracer Enables Early Time PET Imaging in a Humanized Transgenic Mouse Model of B-cell Non-Hodgkins Lymphoma”, Clin Cancer Res (2013) 19: pp. 6820-6829.
[cited by applicant]
Non-Final Office Action mailed on Sep. 24, 2021 in U.S. Appl. No. 16/820,844.
[cited by applicant]
Non-Final Office Action mailed on Feb. 4, 2022 in U.S. Appl. No. 16/801,787.
[cited by applicant]
Non-Final Office Action dated Feb. 10, 2022 in U.S. Appl. No. 16/218,990.
[cited by applicant]
Olson, William C. et al, “Antibody-drug Conjugates Targeing Prostate-Specific Membrane Antigen,” Frontiers in Bioscience (Landmark Edition) 19: pp. 12-33, Jan. 1, 2014.
[cited by applicant]
Alfthan et al., “Properties of a single-chain antibody containing different linker peptides,” Protein Engineering, vol. B, No. 7, pp. 725-731 (1995).
[cited by applicant]
Birtalan et al., “The Intrinsic Contributions of Tyrosine, Serine, Glycine and Arginine to the Affinity and Specificity of Antibodies,” Journal of Molecular Biology, vol. 377, pp. 1518-1528 (2008).
[cited by applicant]
Bork et al., “Proposed acquisition of an animal protein domain by bacteria,” Proceedings of the National Academy of Science, USA, vol. 89, pp. 8990-8994 (1992).
[cited by applicant]
Hallewell et al., “Genetically Engineered Polymers of Human CuZN Superoxide Dismutase,” The Journal of Biological Chemistry, vol. 264, No. 9, pp. 5260-5268 (1989).
[cited by applicant]
Hanes et al., “In vitro selection and evolution of functional proteins by using ribosome display,” Proceedings of the National Academy of Sciences USA, vol. 94, pp. 4937-4942 (1997).
[cited by applicant]
Jacobs et al., “Design of novel FN3 domains with high stability by a consensus sequence approach,” Protein Engineering, Design & Selection, vol. 25, No. 3, pp. 107-117 (2012).
[cited by applicant]
Diem et al., “Selection of high-affinity Centyrin FN3 domains from a simply library diversified at a combination of strand and loop positions.” Protein Engin Design (2014) Selection 27(10): 419-429.
[cited by applicant]
Tannock and Hill. The Basic Science of Oncology. 1998. New York: McGraw-Hill; pp. 357-358.
[cited by applicant]
Song et al. Cancer stem cells—an old idea that's new again: implications for the diagnosis and treatment of breast cancer. Expert Opin Biol Ther 7:4):431-438, 2007.
[cited by applicant]
Binz et al., “High-affinity binders selected from designed ankyrin repeat protein libraries,” Nature Biotechnology, vol. e2, No. 5, pp. 575-582 (May 2004).
[cited by applicant]
Garon et al., “Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer,” The New England Journal of Medicine, vol. 372, No. 21, pp. 2018-2028 (May 21, 2015).
[cited by applicant]
Koide et al., “High-affinity single-domain binding proteins with a binary-code interface,” PNAS, vol. 104, No. 16, pp. 6632-6637(Apr. 17,2017).
[cited by applicant]
Lepenies et al., “The Role of Negative Costimulators Dunng Parasitic Infections,” Endocrine, Metabolic & Immune Disorders—Drug Targets, vol. 8, pp. 279-288 (2008).
[cited by applicant]
McLaughlin et al., “Quantitative Assessment of the Heterogeneity of PD-L 1 Expression in Non-small Cell Lung Cancer (NSCLC),” JAMA Oncol., vol. 2, No. 1, pp. 46-54, (Jan. 2016).
[cited by applicant]
Meinke et al., “Cellulose-Binding Polypeptides from Cellulomonas fimi: Endoglucanase D (CenD), a Family A b-1,4-Glucanase,” Journal of Bactenology, vol. 175, No. 7, pp. 1910-1918 (1993).
[cited by applicant]
Odegrip et al., “CIS display: In vitro selection of peptides from libraries of protein-DNA complexes,” Proceedings of he National Academy of Science USA, vol. 101, No. 9, pp. 2806-2810 (2004).
[cited by applicant]
Olson et al., “Design, expression, and stability of a diverse protein library based on the human fibronectin type III ô€,?omain,” Protein Science, vol. 16, pp. 476-484 (2007).
[cited by applicant]
Roberts et al., “RNA-peptide fusions for the in vitro selection of peptides and proteins,” Proceedings of the National Academy of Science USA, vol. 94, pp. 12297-12302 (1997).
[cited by applicant]
Robinson et al., “Covalent Attachment of Arc Repressor Subunits by a Peptide Linker Enhances Affinity for Operator DNA,” Biochemistry, vol. 35, pp. 109-116 (1996).
[cited by applicant]
Strohl, William R., “Optimization of Fe-mediated effector functions of monoclonal antibodies,” Current Opinion in Biotechnology, vol. 20, pp. 685-691 (2009).
[cited by applicant]
Tie et al., “Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical rials,” International Journal of Cancer, vol. 140, pp. 948-958, (2017).
[cited by applicant]
Wang et al., “VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses,” Journal of Experimental Medicine, vol. 208, No. 3, pp. 577-592 (Mar. 14, 2011).
[cited by applicant]
Watanabe et al., “Gene Cloning of Chitinase A1 from Bacillus circulans WL-12 Revealed Its Evolutionary Relationship to Serratia Chitinase and to the Type III Homology Units of Fibronectin,” Journal of Biological Chemist…
[cited by applicant]
Cooper et al., “4-1 BB (CD 137) controls the clonal expansion and survival of COB T cells in vivo but does not t: ontribute the development of cytotoxicity”, Eur. J_ Immunol., vol. 32, pp. 521-529, 2002.
[cited by applicant]
Gramaglia et al., “Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand,” Eur. J. Immunol., vol. 30, pp. ô €?
[cited by applicant]
DeBenedette et al., “Role of 4-1BB Ligand in Costimulation of T Lymphocyte Growth and its Upregulation on M12 B rymphomas by cAMP,” J_ Exp_ Med., vol. 181, pp. 985-992 (1995).
[cited by applicant]
Langstein et al., “CD137 Induces Proliferation and Endomitosis in Monocytes,” Blood, vol. 94, No. 9, pp. 3161-3168 1999).
[cited by applicant]
Langstein et al., “CD137 (ILA/4-1 Bb), a Member of the TNF Receptor Family, Induces Monocyte Activation via Bidirectional Signaling,” The Journal of Immunology, vol. 160, pp. 2488-2494 (1998).
[cited by applicant]
Lee et al., “4-1BB Promotes the Survival of COB+ T Lymphocytes by Increasing Expression of Bcl-xL and Bfl-11,” The Journal of Immunol., vol. 169, pp. 4882-4888 (2002).
[cited by applicant]
Michel et al., “A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated ymphocytes and is detectable in sera of patients with rheumatoid arthritis,” Eur. J_ Immunol., vol. 28, …
[cited by applicant]
Michel et al., “CD137-induced apoptosis is independent of CD95,” Immunology, vol. 98, pp. 42-46 (1999).
[cited by applicant]
Schwarz et al., “ILA, a Member of the Human Nerve Growth FactorfTumor Necrosis Factor Receptor Family, Regulates T-Lymphocyte Proliferation and Survival,” Blood, vol. 87, No. 7, pp. 2839-2845 (Apr. 1, 1996).
[cited by applicant]
Shuford et al., “4-18B Costimulatory Signals Preferentially Induce COB+ T Cell Proliferation and Lead to the amplification In Vivo of Cytotoxic T Cell Responses,” J_ Exp_ Med., vol. 186, No. 1, pp. 47-55 (Jul. 7, 1997).
[cited by applicant]
Takahashi et al., “Cutting Edge: 4-1 BB Is a Bona Fide COB T Cell Survival Signal,” J Immunol., vol. 162, pp. 0037-5040 (1999).
[cited by applicant]
Alderson et al., “Molecular and Biological Characterization of Human 4-1 BB and its Ligand”, Eur. J_ Immunol., vol. N, pp. 2219-2227, 1994.
[cited by applicant]
Hurtado et al., “Potential role of 4-1 BB in T cell Activation Comparison with the Costimulatory Molecule CD28”, Journal of Immunology, vol. 155, pp. 3360-3367, 1995.
[cited by applicant]
Hurtado et al., “Signals through 4-1BB are Costimulatory to previously activated splenic T cells and inhibit activation-induced cell death”, Journal of Immunology, vol. 158, pp. 2600-2609, 1997.
[cited by applicant]
Maus et al., Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs Expressing ligands for the T-cell receptor, CD28 and 4-1BB Nature Biotechnology, vol. 20, pp. 143-148, Feb. 20…
[cited by applicant]
Michel et al., “Expression of soluble CD137 correlates with activation-induced cell death of lymphocytes”, Cytokine, vol. 12, No. 6, pp. 742-746, 2000.
[cited by applicant]
Zhou et al., Characterization of human homologue of 4-1 BB and its ligand, Immunology Letters, vol. 45, pp. p7-73, 1995.
[cited by applicant]
Pauly et al., CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal t; enters, Journal of Leukocyte Biology, vol. 72, pp. 35-42, Jul. 2002.
[cited by applicant]
Langstein et al., Identification of CD137 as a potent monocyte survival factor, Journal of Leukocyte Biology, vol. 65, pp. 829-833, Jun. 1999.
[cited by applicant]
Kwon et al., cDNA sequences of two inducible T-cell genes, Proc. Natl. Acad. Sci., vol. 86, pp. 1963-1967, Mar. 1989.
[cited by applicant]
Lehmann et al., Engineering proteins for thermostability the use of sequence alignments versus rational design and directed evolution, Current Opinion in Biotechnology, vol. 12, pp. 371-375 (2001).
[cited by applicant]
Chiba et al., Amyloid Fibril Formation in the Context of Full-length Protein Effects of Praline mutations on the Amyloid fibril formation of b2-Microglobulin, Journal of Biological Chemistry, vol. 278, No. 47, pp. 47016…
[cited by applicant]
Goldberg et al., “Engineering a Targeted Delivery Platform using Centyrins” Protein Engineering, Design & selection, vol. 29, No. 12, pp. 563-572, 2016.
[cited by applicant]
Strand et al., “Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-lodophenethylmaleimide Decreases Renal Uptake of Radioactivity”; Chemitry Open, vol. 4, pp. 174-182, 2015.
[cited by applicant]
Hylarides et al., “Preparation and in Vivo Evaluation of an N-9p-[1251]1odophenethyl) maleimide—Antibody Conjugate” Bioconjugate Chem., vol. 2, pp. 435-440, 1991.
[cited by applicant]
Lohse et al., Fluorescein-Conjugated Lysine monomers for Solid Phase Synthesis of Fluorescent Peptides and PNA Pligomers Bioconjugate Chem, vol. 8, pp. 503-509, 1997 .pdf.
[cited by applicant]
Binz, et al., “Engineered proteins as specific binding reagents,” Current Opinion in Biotechnology, 16: 459-469 (2005).
[cited by applicant]
Tang et al, “Anti-Transferrin Receptor-Modified Amphotericin B-Loaded PLA-PEG Nanoparticles Cure Candidal Meningitis and Reduce Durg Toxicity,” Oct. 5, 2015, International Journal of Medicine, 2015:10, pp. 6227-6241.
[cited by applicant]